Start here if you're new
what it is
It sells crop chemicals, plant nutrition, and pest-control products across 26 countries through a portfolio built by acquisitions.
how it gets paid
Last year Amer. Vanguard made $547M in revenue. Crop protection was the main engine at $300.9M, or 55% of sales.
what just happened
Q3 2025 GAAP EPS was $(0.43); adjusted EPS was $(0.10), missing a $(0.08) consensus. Net sales were $119M, with gross margin near 29%.
At a glance
C+ balance sheet — struggling to keep the lights on
25/100 earnings predictability — expect surprises
2.7% return on capital — nothing to write home about
-$2.54 fy2024 eps est
$547M fy2024 rev est
xvary composite: 38/100 — weak
What they do
It sells crop chemicals, plant nutrition, and pest-control products across 26 countries through a portfolio built by acquisitions.
This business wins by already being in the field. AVD has more than 1,000 product registrations in 56 nations and operates in 26 countries, so if you need a niche crop or pest-control product, the distribution and approvals are already there. Product registrations are regulatory permission slips, which means the hard part is getting approved, and AVD already has a lot of the paperwork.
How they make money
$547M
annual revenue
Crop protection
$300.9M
Crop nutrition
$82.1M
Turf & ornamentals
$65.6M
Commercial & consumer pest control
$98.4M
The products that matter
herbicides, insecticides, fungicides
Crop Protection
$~301M · about 55% of revenue
it is the main business line, and that concentration matters. when farmer demand weakens here, most of the company feels it.
core revenue
soil fumigants and nutrients
Soil Health
$~246M · about 45% of revenue
this bundles the non–crop-protection segments. at roughly 45% combined, it matters enough to help, but crop protection still drives the cycle.
secondary segment
Key numbers
$194M
long-term debt
The debt load is larger than the company's roughly $116M market value, so your upside depends on a real turnaround, not a story.
-18.6%
operating margin
Operating margin means profit after running the business, before interest and taxes, so what matters is AVD is losing money on the core operation.
$547M
annual revenue
The company still moves serious product volume, which is why even a small margin recovery would matter a lot.
63%
debt to capital
Debt to capital means how much of the company's funding stack is borrowed money, so 63% tells you leverage is doing a lot of the work.
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 3 — safer than 50% of stocks
- price stability 30 / 100
- long-term debt $194M (63% of capital)
C+ — balance sheet grade and long-term debt are flagged. this stock carries more risk than average.
Total return vs. market
Return history isn't available for AVD right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Q3 2025 GAAP EPS was $(0.43); adjusted EPS was $(0.10) vs. a $(0.08) consensus, with gross margin near 29%.
The bigger picture is worse than one bad print. Full-year EPS collapsed to -$2.54 from $0.26, and operating margin for FY2024 was -18.6%, which says the problem is structural until proven otherwise.
$119M
net sales (Q3)
$(0.43)
gaap eps
~29%
gross margin
the number that mattered
The number that mattered was -18.6% operating margin for FY2024 because it tells you revenue is not the issue. Profitability is.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
your biggest risk is crop protection demand staying soft while $194M of long-term debt towers over a $116M market cap.
med
farm spending stays weak
FY2025 revenue fell 6% to $515M. when the main customer base pulls back, AVD does not have a high-margin segment to hide in.
impact: most of the business sits in crop protection, which is about 55% of revenue.
med
leverage limits your margin for error
long-term debt is $194M, or 63% of capital, while the market cap is about $116M. that gap matters because equity holders are junior to the balance sheet.
impact: debt is about 1.7x the equity value the market is giving the company today.
med
the turnaround target misses
management is aiming for $44M–$48M of 2026 adjusted EBITDA. if that number slips, investors have less reason to trust cost cuts or product launches.
impact: one missed operating target would leave you with the same debt load and no clean proof of recovery.
this is a leveraged turnaround tied to a weak end market. if revenue keeps sliding below $515M or 2026 adjusted EBITDA misses $44M–$48M, the equity story gets thinner fast.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
2026 adjusted EBITDA: $44M–$48M
this is the number that matters. if management lands inside this range, the turnaround starts to look measurable instead of aspirational.
trend
revenue stops shrinking
FY2025 revenue was $515M after a 6% decline. you want the next reports to show stabilization before you ask the market for a rerating.
risk
debt stays above the equity value
$194M of long-term debt versus a $116M market cap is not normal small-cap breathing room. if that relationship does not improve, upside stays capped by financing risk.
calendar
the next earnings release
you are looking for two things in the same report: progress toward the EBITDA target and proof that sales are no longer stepping down.
Analyst rankings
earnings predictability
25 / 100
in human-speak, analysts do not trust this business to deliver clean, steady earnings.
balance sheet strength
C+
that is a warning label, not a death sentence. you can own it, but you do not get to ignore leverage.
source: institutional data
Institutional activity
institutional ownership data for AVD is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$5
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive